Metabolic Syndrome linked to bladder Cancer Risk: Study

Result: In the bibliometric analysis, 147 papers were included, and information on countries, institutions, authors, journals and keywords from Web of Science was analyzed and visualized. For the meta-analysis, 11 studies involving 665,164 patients were included. The pooled analysis of six case-control studies showed that patients with MetS had a higher risk of bladder cancer compared to the non-MetS control group (OR = 1.62, 95% CI: 1.08–2.43, P < 0.01). Analysis of MetS components revealed that diabetes (OR = 0.44, 95% CI: 0.32–0.61, P < 0.01), low high-density lipoprotein (HDL) (OR = 0.29, 95% CI: 0.19–0.44, P < 0.01) and high triglycerides (OR = 0.59, 95% CI: 0.39–0.88, P < 0.01) were associated with an increased risk of bladder cancer. In contrast, hypertension (OR = 0.84, 95% CI: 0.62–1.12, P > 0.05) and obesity (OR = 0.8, 95% CI: 0.44–1.45, P > 0.05) showed no significant association with bladder cancer risk.

This study provided valuable insights into the association between MetS and bladder cancer risk by identifying past research trends and hotspots. MetS and its components, such as diabetes, low HDL and high triglycerides, were associated with an increased risk of bladder cancer.

Reference:

Yuan, Y., Liu, T., Yao, Y. et al. Metabolic syndrome and bladder cancer risk: a comprehensive evidence synthesis combining bibliometric and meta-analysis approaches. BMC Urol 25, 132 (2025). https://doi.org/10.1186/s12894-025-01812-9